By far the most frequently mutated genes in the pancreatic tumor cohorts are KRAS with 75% of affected patients and TP53 with 65% followed by CDKN2A and SMAD4 with 20%, respectively. The gene discussed is KRAS; the disease is pancreatic neoplasm.